

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Florack, et al.

Examiner: Unassigned

Serial No.: 10/574,888

Group Art Unit: Unassigned

International Application No:
PCT/NL2004/000708


Docket No.: 294-248 PCT/US

Filed: April 7, 2006

Confirmation No.: 3362

For: CHIMERIC CARRIER MOLECULES FOR
THE PRODUCTION OF MUCOSAL VACCINES

Date: March 12, 2008

Mail Stop PCT
Attention: PCT Legal Staff
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to: Mail Stop Sequence,
U.S. Patent and Trademark Office, P.O. Box 1450,
Alexandria, VA 22313-1450 on March 12, 2008Signature **PETITION TO REVIVE**

A Notification of Abandonment was mailed by the Office on February 12, 2008. The reason stated for the Notification of Abandonment is "Sequence Listing, filed 10/03/07 could not be accepted. See attached CRFD dated 2/11/08." According to the Notice, the above-identified application became abandoned for failure to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495.

A Notification of Missing Requirements was mailed by the Office January 5, 2007. A response, including a sequence listing was filed February 5, 2007. A Notification of Defective Response was received on October 2, 2007, well after the six month statutory period (with extensions) running from the Notification of Missing Requirements, had expired.

On October 30, 2007 a response was filed with the Office, amending the sequence listing and providing a computer readable format (CRF). On February 11, 2008, Applicants' attorney contacted the Office for information regarding a filing receipt. Applicants' attorney noticed that the sequence listing in PAIR in the Image File Wrapper was not the sequence sent by the attorney to the Office. In order to obtain information regarding which paper

document was sent to the Office and why the original sequence, rather than the amended sequence was in the Image File Wrapper, attorney contacted several individuals within the Office.

Applicants' attorney was directed to contact Mr. Scott Priebe at 571-272-0733 for information regarding the sequence listing and problems with PAIR. After discussing the sequence listing received, Applicants' attorney was instructed that the CRF contained the amended sequence listing; however that new listing contained two new errors.

Mr. Priebe instructed Applicants' attorney that the PAIR system was exhibiting communication errors between the identification of incorrect responses and the triggering of subsequent Office instruction. Therefore, Mr. Priebe indicated he would manually trigger a response within the system and Applicants' attorney should await a new Notice of Defective Response. However, rather than receiving a new Notice of Defective Response, Applicants' attorney received a Notice of Abandonment.

Applicant submits this petition under 37 CFR 1.137(b) to revive this unintentionally abandoned application and encloses herewith:

1. Please charge Deposit Account No. 08-2461 the amount of \$1,540.00 to cover the petition fee for a non-small entity; and
2. A proper reply in the form of an Amendment and Communication to Comply with Notification of Defective Response
3. A copy of the Notification of Defective Response

A Terminal Disclaimer is not enclosed since this international application has an international filing date after June 8, 1995.

In the event that any additional fees are due, the Patent Office is authorized to charge Deposit Account No. 08-2461 for such fees.

Applicant(s): Florack, et al.
Serial No.: 10/574,888
Filed: April 7, 2006
Petition to Revive
Page 3 of 3

The entire delay in filing the correct response to the Notice of Defective Response from the due date until the filing of a grantable petition under 37 CFR 1.37(b) was unintentional.

Respectfully submitted,



Ellen N. Hollcroft
Registration No. 58,452
Attorney for Applicant(s)

HOFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
ENH:jp

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Florack, et al.

Examiner: Unassigned

Serial No.: 10/574,888

Group Art Unit: Unassigned

Filed: April 7, 2006

Docket No.: 294-248 PCT/US

Confirmation No.: 3362


For: CHIMERIC CARRIER MOLECULES FOR THE
PRODUCTION OF MUCOSAL VACCINES

Date: March 12, 2008

Mail Stop Sequence
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to: Mail Stop Sequence,
U.S. Patent and Trademark Office, P.O. Box 1450,
Alexandria, VA 22313-1450 on **March 12, 2008**

Signature



**AMENDMENT AND COMMUNICATION TO
COMPLY WITH NOTIFICATION OF DEFECTIVE RESPONSE**

Sir:

In response to a Notification of Defective mailed October 2, 2007, Applicants
enclose herewith the following:

1. A substitute CD containing the sequence listing in computer-readable
form (CRF);
2. A substitute paper copy of the sequence listing; and
3. Copy of Notification of Abandonment.

According examiner Scott Priebe, the initial response to the notice was
inadequate in that sequences 4 and 5 stated "Nucleic Acid Sequence" rather than
"Artificial Sequence" and there was no <220> or <223> as required.


Under 37 C.F.R. 1.821(f), the Applicants' Attorney hereby states that the
contents of the substitute computer readable form and the substitute paper copy filed
herewith are the same.

Applicant(s): Florack, et al.
Serial No.: 10/574,888
Filed: April 7, 2007
Amendment and Communication to Comply
with Notification of Defective Response
Page 2 of 2

Under 37 C.F.R. §1.821(g), the Applicants' Attorney also states that the substitute computer readable form and paper copy of the sequence listing do not include any new matter.

Accordingly, it is respectfully requested that the substitute computer readable form and paper copy of the sequence listing be entered into the application.

Respectfully submitted,



Ellen N. Hollcroft
Registration No. 58,452
Attorney for Applicant(s)

HOFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
ENH:jp




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/574,888	FIRST NAMED APPLICANT Dionisjus Elisabeth Antonius Florack	ATTY. DOCKET NO. 294-248 PCT/US
---	---	------------------------------------

23869
HOFFMANN & BARON, LLP
6900 JERICHO TURNPIKE
SYOSSET, NY 11791



INTERNATIONAL APPLICATION NO. PCT/NL04/00708	
I.A. FILING DATE 10/08/2004	PRIORITY DATE 10/09/2003

CONFIRMATION NO. 3362
371 ABANDONMENT/TERMINATION
LETTER



Date Mailed: 02/21/2008

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- Sequence Listing, filed 10/03/07 could not be accepted. See attached CRFD dated 02/11/08

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2007; month=12; day=4; hr=9; min=53; sec=59; ms=804;]

=====

Reviewer Comments:

Seq Id 4 and 5

Invalid response for <213>, If <213> responses are Aritificial or
Unknown please give the source of genetic material.

Application No: 10574888

Version No: 2.0

Input Set:

Output Set:

Started: 2007-11-14 19:18:33.328

Finished: 2007-11-14 19:18:35.056

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 728 ms

Total Warnings: 18

Total Errors: 0

No. of SeqIDs Defined: 18

Actual SeqID Count: 18

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 402	Undefined organism found in <213> in SEQ ID (3)
W 402	Undefined organism found in <213> in SEQ ID (4)
W 402	Undefined organism found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 402	Undefined organism found in <213> in SEQ ID (7)
W 402	Undefined organism found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 402	Undefined organism found in <213> in SEQ ID (10)
W 402	Undefined organism found in <213> in SEQ ID (11)
W 402	Undefined organism found in <213> in SEQ ID (12)
W 402	Undefined organism found in <213> in SEQ ID (13)
W 402	Undefined organism found in <213> in SEQ ID (14)
W 402	Undefined organism found in <213> in SEQ ID (15)
W 402	Undefined organism found in <213> in SEQ ID (16)
W 402	Undefined organism found in <213> in SEQ ID (17)
W 402	Undefined organism found in <213> in SEQ ID (18)

SEQUENCE LISTING

<110> Plant Research International B.V.

<120> Chimeric Carrier Molecules for the Production of Mucosal Vaccines

<130> 294-248 PCT/US

<140> 10574888

<141> 2007-11-14

<150> PCT/NL2004/000708

<151> 2004-10-08

<150> EP 03078192.6

<151> 2003-10-09

<160> 18

<170> PatentIn version 3.4

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 1

Ser Glu Lys Asp Glu Leu

1 5

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> KDEL signal Peptide

<400> 2

Lys Asp Glu Leu

1

<210> 3

<211> 20

<212> PRT

<213> Artifical Sequence

<220>

<223> core CPV epitope

<400> 3

Ser Asp Gly Ala Val Gln Pro Asp Gly Gly Gln Pro Ala Val Arg Asn
1 5 10 15

Glu Arg Ala Thr
20

<210> 4

<211> 26

<212> DNA

<213> Nucleic Acid Sequence

<400> 4

gttcacccctt ttcactgaat tctgcg

26

<210> 5

<211> 26

<212> DNA

<213> Nucleic Acid Sequence

<400> 5

cgcagaattc agtgaaaagg atgaac

26

<210> 6

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> HA epitope

<400> 6

Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu
1 5 10

<210> 7

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 7

gggtgatc acattcaaga gcggtgaaac atttcaagtc

40

<210> 8

<211> 21

<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 8
atgataatca tcgcaagacc g

21

<210> 9
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 9
gtgacgaaga caacatgaat aaagtataat gttatgtt

38

<210> 10
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 10
gtgacgaatt ctatggatcc cctggagcgt agtttttcat actgattgcc

50

<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 11
gtgacggatc cggcttccaa gg

22

<210> 12
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 12
gtgacgaaga caagatctta cttgtacaac tcatcca 37

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 13
gatcgaccgg ggagatctaa gtcacgagac cgtctgactt ctggagaact gc 52

<210> 14
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 14
tctggtggat ccgcagatca ctcaacgacc tccgg 35

<210> 15
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 15
tctggtctcg agatcccat attgttcca tc 32

<210> 16
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 16
gatcgaggat ccaagtcac aaactaaaga ccgcatttcg 40

<210> 17
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 17
gatccatggc aaaaatcact ttgtcatc 28

<210> 18
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 18
atcggatccc tattaagcgg ctctagctaa ttg 33

294-248 3PCT US_ST25.txt
SEQUENCE LISTING

<110> Plant Research International B.V.
 <120> Chimeric Carrier Molecules for the Production of Mucosal Vaccines
 <130> 294-248 PCT/US
 <140> 10/574,888
 <141> 2006-04-07
 <150> PCT/NL2004/000708
 <151> 2004-10-08
 <150> EP 03078192.6
 <151> 2003-10-09
 <160> 18
 <170> PatentIn version 3.4
 <210> 1
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Synthetic peptide
 <400> 1
 Ser Glu Lys Asp Glu Leu
 1 5
 <210> 2
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Synthetic Peptide
 <400> 2
 Lys Asp Glu Leu
 1
 <210> 3
 <211> 20
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> core CPV epitope
 <400> 3
 Ser Asp Gly Ala Val Gln Pro Asp Gly Gly Gln Pro Ala Val Arg Asn
 1 5 10 15

Glu Arg Ala Thr
20

<210> 4
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 4
gttcatacctt ttactgaat tctgcg

26

<210> 5
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 5
cgcagaattc agtgaaaagg atgaac

26

<210> 6
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> HA epitope

<400> 6

Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu
1 5 10

<210> 7
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 7
ggtgatcatc acattcaaga gcggtgaaac atttcaagtc

40

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 8

atgataatca tcgcaagacc g 21

<210> 9
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 9
 gtgacgaaga caacatgaat aaagtaaaat gttatgtt 38

<210> 10
 <211> 50
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 10
 gtgacgaatt ctatggatcc cctggagcgt agtttttcat actgattgcc 50

<210> 11
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 11
 gtgacggatc cggtttccaa gg 22

<210> 12
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 12
 gtgacgaaga caagatctta cttgtacaac tcatcca 37

<210> 13
 <211> 52
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 13
 gatcgaccg ggagatctaa gtcacagac cgtctgactt ctggagaact gc 52

<210> 14
 <211> 35
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 14
 tctggtggat ccgcagatca ctcaacgacc tccgg 35

<210> 15
 <211> 32
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 15
 tctggtctcg agatcccat attgttcca tc 32

<210> 16
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 16
 gatcgaggat ccaagtcac aaactaaaga ccgcatttcg 40

<210> 17
 <211> 28
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer


 <400> 17
 gatccatggc aaaaatcact ttgtcatc 28

<210> 18
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 18
 atcgatccc tattaagcgg ctctagctaa ttg 33

UNITED STATES POSTAGE



\$01.82⁰⁰

02 1A 0004606884 MAR 12 2008

MAILED FROM ZIP CODE 11791



HOFFMANN & BARON, LLP

ATTORNEYS AT LAW

6900 JERICHO TURNPIKE

SYOSSET, NEW YORK 11791-4407

TO:

Mail Stop PCT

Attention: PCT Legal Staff

United States Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

FIRST CLASS MAIL

USPTO MAIL CENTER

MAR 17 2008

RECEIVED

USPTO MAIL

MAR 17

REC